[
  {
    "ts": null,
    "headline": "Guggenheim Sets $62 Target on Bristol-Myers Squibb Company (BMY) After FDA Priority Review",
    "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company is one of the most undervalued stocks on our list. On Friday, December 12, 2025, TheFly reported that Guggenheim upgraded BMY’s stock rating from Neutral to Buy and set a new price target of $62, reflecting growing […]",
    "url": "https://finnhub.io/api/news?id=fa7addc227851c9211947d878cf377a35683da8404c428d83c92f2c7ac48fb4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766009319,
      "headline": "Guggenheim Sets $62 Target on Bristol-Myers Squibb Company (BMY) After FDA Priority Review",
      "id": 137817295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company is one of the most undervalued stocks on our list. On Friday, December 12, 2025, TheFly reported that Guggenheim upgraded BMY’s stock rating from Neutral to Buy and set a new price target of $62, reflecting growing […]",
      "url": "https://finnhub.io/api/news?id=fa7addc227851c9211947d878cf377a35683da8404c428d83c92f2c7ac48fb4a"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Healthcare Stocks Just Declared Dividend Raises",
    "summary": "The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.",
    "url": "https://finnhub.io/api/news?id=68aa261439a7859bc88057935713473d3ef75afbe7586e5f5d3815071c31e9c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766008800,
      "headline": "These 2 Healthcare Stocks Just Declared Dividend Raises",
      "id": 137817296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.",
      "url": "https://finnhub.io/api/news?id=68aa261439a7859bc88057935713473d3ef75afbe7586e5f5d3815071c31e9c6"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: This ETF Stinks",
    "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
    "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765997441,
      "headline": "SCHD: This ETF Stinks",
      "id": 137814928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364623580/image_1364623580.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
      "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=8a2bffc7b12d87ee467f9e0a4af6613c3f10faf3c7e51f0382b5082c44dae0e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765980002,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 137817297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=8a2bffc7b12d87ee467f9e0a4af6613c3f10faf3c7e51f0382b5082c44dae0e6"
    }
  },
  {
    "ts": null,
    "headline": "Harbour BioMed and BMS sign multi-specific antibody collab",
    "summary": "Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.",
    "url": "https://finnhub.io/api/news?id=f4b3b9e7d271936a2d497511c35b74c87de149d085abe9e06f88d98769377e62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765971288,
      "headline": "Harbour BioMed and BMS sign multi-specific antibody collab",
      "id": 137817298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.",
      "url": "https://finnhub.io/api/news?id=f4b3b9e7d271936a2d497511c35b74c87de149d085abe9e06f88d98769377e62"
    }
  },
  {
    "ts": null,
    "headline": "Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies",
    "summary": "Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.",
    "url": "https://finnhub.io/api/news?id=b12487593f707b18799a9dee903846e97b425839e05d90a97cfced33e9380bd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765929840,
      "headline": "Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies",
      "id": 137806481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.",
      "url": "https://finnhub.io/api/news?id=b12487593f707b18799a9dee903846e97b425839e05d90a97cfced33e9380bd5"
    }
  }
]